On March 7, 2013, Chen, Shaoqing; De Vicente Fidalgo, Javier; Hamilton, Matthew Michael; Hermann, Johannes Cornelius; Kennedy-Smith, Joshua; Li, Hongju; Lovey, Allen John; Lucas, Matthew C.; Luk, Kin-Chun Thomas; Lynch, Stephen M.; O’Yang, Counde; Padilla, Fernando; Schoenfeld, Ryan Craig; Sidduri, Achyutharao; Soth, Michael; Wang, Ce; Wovkulich, Peter Michael; Zhang, Xiaohu published a patent.Safety of (S)-1-Methoxypropan-2-amine hydrochloride The title of the patent was Pyrrolopyrazines as kinase inhibitors and their preparation. And the patent contained the following:
The invention relates to the use of pyrrolopyrazine derivatives of formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases. Compounds of formula I wherein R is H; R’ is lower alkoxy and (un)substituted alkyl; RR’ can be taken together to form (un)substituted heterocycloalkyl; Q is (un)substituted bicyclic heteroaryl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their kinase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 0.00172 μM. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Safety of (S)-1-Methoxypropan-2-amine hydrochloride
The Article related to pyrrolopyrazine preparation kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of (S)-1-Methoxypropan-2-amine hydrochloride
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem